Compare MKTX & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MKTX | PTCT |
|---|---|---|
| Founded | 2000 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 5.5B |
| IPO Year | 2004 | 2006 |
| Metric | MKTX | PTCT |
|---|---|---|
| Price | $164.60 | $65.66 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 16 |
| Target Price | ★ $204.38 | $80.94 |
| AVG Volume (30 Days) | 401.7K | ★ 976.6K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.90% | N/A |
| EPS Growth | N/A | ★ 264.48 |
| EPS | 6.64 | ★ 7.78 |
| Revenue | ★ $397,471,000.00 | $264,734,000.00 |
| Revenue This Year | $9.90 | N/A |
| Revenue Next Year | $7.38 | $19.30 |
| P/E Ratio | $24.71 | ★ $8.50 |
| Revenue Growth | 7.45 | ★ 36.19 |
| 52 Week Low | $156.17 | $35.95 |
| 52 Week High | $232.84 | $87.50 |
| Indicator | MKTX | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 30.32 | 45.34 |
| Support Level | $158.44 | $61.43 |
| Resistance Level | $176.74 | $69.23 |
| Average True Range (ATR) | 4.18 | 2.27 |
| MACD | -1.93 | 0.29 |
| Stochastic Oscillator | 7.36 | 50.65 |
Founded in 2000, MarketAxess is a leading electronic fixed-income trading platform that connects broker/dealers and institutional investors. The company is primarily focused on credit based fixed income securities with its main trading products being US investment-grade and high-yield bonds, Eurobonds, and Emerging Market corporate debt. Recently the company has expanded more aggressively into Treasuries and municipal bonds with the acquisitions of LiquidityEdge and MuniBrokers in 2019 and 2021, respectively. The company also provides pre- and post-trade services with its acquisition of Regulatory Reporting Hub from Deutsche Börse Group in 2020 adding to its product offerings.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.